Ovarian Cancer   

Since there is no overlap between chemo regimens for these cancers, how would you sequence treatment? 

Do you extrapolate from first line maintenance studies for duration of therapy?

Considering updated trials, such as final OS data from NOVA, and recent society guideline updates?

Front-line PARP inhibitor maintenance therapy discontinued without progression.

Given the crossover that occurred in the various clinical trials and the potential for prolonged disease duration, how do you integrate OS, PFS, treat...

Does your approach change depending on the patients initial somatic BRCA status?

In your practice, what is the proportion of patients receiving neoadjuvant chemotherapy who are diagnosed with VTE? Does this differ from patients rec...

Would your systemic therapy choice be more similar to treatment of ovarian carcinoma or soft tissue sarcoma?

How would you approach the treatment if the tumor is PDL1+?

How does your approach vary based on residual disease left at the time of surgery? Please specify your approach for the amount of residual disease at ...

Do you prophylactically start all patients on B12, B-complex, and/or omega-3? If so, what dose? What about ice mittens and booties?

Considering the treatment of platinum resistant ovarian cancer as done in the AURELIA trial (Pujade-Lauraine et al., PMID 24637997).

Assuming low risk of progression to AML and eligible for low-risk chemotherapies per hematologic/oncology.

Genes such as ATM, CHEK2, PALB2, RAD51C/D, BRIP1 seem to show some potential increased risk of ovarian cancer. Should these patients under prophylacti...

s/p optimal debulking. If this was an early-stage cancer would it change your adjuvant therapy recommendations?

Recurrence picked up incidentally on CT. No germ line mutations, somatic tumor testing of node resulted negative. PET confirmed isolated recurrence

Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses? 

What specific platforms for determining somatic BRCA and HRD status do you use for a patient who does not carry a germline BRCA mutation?

How do the 5 year results of SOLO-1 at ESMO 2020 impact your recommendations?

Are there clinical factors which help stratify? Does your practice vary based on mutation status (BRCA+ vs HRD+?)

Is MDS/AML risk increased with longer duration of therapy? Does your approach differ for patients who are BRCA+/HRD vs wild type/HRP?

Given recent approval of niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or prima...

Does your strategy differ if the patient is on maintenance PARP inhibitor, bevacizumab, both, or neither? 

Based on recent PAOLA-1

SOLO1 trial studied stage 3/4 patients.

Or do you wait for platinum resistance?

Is it reasonable to use single agent carboplatin for elderly patients?

Would you approach this situation as synchronous primaries (eg. FIGO IA in both) or as a locally advanced endometrial cancer (FIGO IIIA)? What adjuva...